Table 1: Recommended Starting Dose for Moderate and Severe Renal Impairment and End-Stage Renal Disease 
Guidelines for Dose Modification provided below are based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE Version 2.0).
Table 2: SYLATRON Dose Modifications 
Reconstitute SYLATRON with 0.7 mL of Sterile Water for Injection, USP.
Table 3: Reconstitution of SYLATRON Single-Use Vials 
